Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of REBACIN and interferon alpha-2b in clearing persistent high-risk HPV infection
ChiCTR2100043973Phase 3Recruiting
- Sponsor
- Anhui Province Maternity and Child Health Hospital
- Start
- Jul 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ribostamycin and interferon alfa-2b in human papillomavirus infection (3 arms), sponsored by Anhui Province Maternity and Child Health Hospital. Primary endpoints: HPV E6/E7 mRNA and HPV-DNA genotyping test. Started Jul 2020; status: recruiting.
02
Drugs
ribostamycininterferon alfa-2b
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2100043973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043973.